Minneapolis, United States
Emerging Therapy Solutions® (ETS) is a health tech startup founded in 2018 in the United States. The company's mission is reflected in its slogan "What is my risk and what's coming? Who should I cover? Where do I get the best outcomes and clinical value?" ETS aims to assist healthcare payers in managing the risks associated with high-cost therapies for rare and complex conditions.
ETS made a strategic move in 2020 by acquiring LifeTrac, a company with over 30 years of experience in bone marrow and solid organ transplants, as well as strong provider relationships and agreements. This acquisition bolstered ETS's expertise in cell and gene therapies, creating a comprehensive suite of services for payers covering solid organ and bone marrow transplants, cell and gene therapies, and other specialized treatments.
In March 26, 2024, ETS secured a $5.00M funding in a venture round. Although the details of the investor(s) are not disclosed, this investment signifies confidence in the potential of ETS and its innovative approach to managing healthcare risks.
Emerging Therapy Solutions is positioned to address crucial gaps in the management of high-cost therapies, making it an attractive prospect for investors seeking innovative solutions in the Health Care and Insurance industries.
Jointechlabs, Inc.
